References
•Nephrogenic
Systemic Fibrosis (NSF) with gadolinium-containing magnetic resonance imaging (MRI) contrast agents
– Update. MHRA=Medicines and Healthcare products Regulatory Agency Web site. Available
at: http://www.mhra.gov.uk/Safetyinformation/Safetywarningsalertsandrecalls/Safetywarningsandmessagesformedicines/CON2031543.
Accessed March 19, 2008.
•Update
on Magnetic Resonance Imaging (MRI) Contrast Agents Containing Gadolinium and Nephrogenic Fibrosing
Dermopathy Public Health Advisory. Food and Drug Administration Web site. Available at: http://www.fda.gov/CDER/DRUG/advisory/gadolinium_agents_20061222.htm.
Accessed
March 19, 2008.